Study of effects of DDP4 inhibitors and metformin on interleukin-1ß and metabolic parameters in patients with type 2 diabetes in Iraqi

Hyperglycemia is caused by aberrant insulin synthesis, action, or both in many metabolic disorders. DM is a group of illnesses. This study evaluated DPP-4 and metformin's impact on metabolic indicators in type 2 diabetes and newly diagnosed individuals. This study included 30 to 83-year-olds. In this research, type 2 diabetics were divided into three groups based on their medication. Control group healthy patients numbered 49. DDP4 and IL-1ß levels were measured by ELISA, and biochemical features varied from healthy groups. Except for the metformin-only group, the DDP4 inhibitor drug is relevant in all biochemical markers. Newly diagnosed type 2 diabetics showed higher IL-1 levels than those taking DDP4 inhibitors and metformin. Higher IL-1 levels increased IL-1 activation. A systemic inflammatory process may indicate beta-cell death in early type 2 diabetes. DDP4 and DDP4 may assist more people, according to these data. Current recommendations recommend DDP inhibitors for type 2 diabetic management. This study focuses on diabetic cytokines like IL-1ß.